Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesLiabilities and Shareholders EquityMinority InterestNon-Current AssetsOperating LeasesOther Non-Current AssetsPayablesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

MoonLake Immunotherapeutics (MLTX) Long-Term Investments (2020 - 2022)

MoonLake Immunotherapeutics' Long-Term Investments history spans 3 years, with the latest figure at $115.1 million for Q1 2022.

  • Quarterly Long-Term Investments changed 0.02% to $115.1 million in Q1 2022 from the year-ago period, while the trailing twelve-month figure was $115.1 million through Mar 2022, changed 0.02% year-over-year, with the annual reading at $115.0 million for FY2021, 0.02% changed from the prior year.
  • Long-Term Investments came in at $115.1 million for Q1 2022, roughly flat from $115.0 million in the prior quarter.
  • In the past five years, Long-Term Investments ranged from a high of $115.1 million in Q1 2022 to a low of $115.0 million in Q4 2020.
  • The 3-year median for Long-Term Investments is $115.0 million (2021), against an average of $115.0 million.
  • Year-over-year, Long-Term Investments increased 0.02% in 2021 and then increased 0.02% in 2022.
  • MoonLake Immunotherapeutics' Long-Term Investments stood at $115.0 million in 2020, then grew by 0.02% to $115.0 million in 2021, then increased by 0.01% to $115.1 million in 2022.
  • Per Business Quant, the three most recent readings for MLTX's Long-Term Investments are $115.1 million (Q1 2022), $115.0 million (Q4 2021), and $115.0 million (Q3 2021).